These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24915856)

  • 1. The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis.
    Gandaglia G; Karakiewicz PI; Abdollah F; Becker A; Roghmann F; Sammon JD; Kim SP; Perrotte P; Briganti A; Montorsi F; Trinh QD; Sun M
    Eur J Surg Oncol; 2014 Dec; 40(12):1706-15. PubMed ID: 24915856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
    Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
    Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
    Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
    BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.
    Abdollah F; Suardi N; Cozzarini C; Gallina A; Capitanio U; Bianchi M; Sun M; Fossati N; Passoni NM; Fiorino C; Di Muzio N; Karakiewicz PI; Rigatti P; Montorsi F; Briganti A
    Eur Urol; 2013 Jun; 63(6):998-1008. PubMed ID: 23122664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
    Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
    Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria.
    Gandaglia G; Karakiewicz PI; Briganti A; Trudeau V; Trinh QD; Kim SP; Montorsi F; Nguyen PL; Abdollah F; Sun M
    Int J Urol; 2015 Jan; 22(1):89-95. PubMed ID: 25141965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
    Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis.
    Sun M; Abdollah F; Bianchi M; Trinh QD; Jeldres C; Tian Z; Shariat SF; Widmer H; Zorn K; Menon M; Montorsi F; Perrotte P; Karakiewicz PI
    Eur Urol; 2011 Dec; 60(6):1152-9. PubMed ID: 21868147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis.
    Gandaglia G; Becker A; Trinh QD; Abdollah F; Schiffmann J; Roghmann F; Tian Z; Montorsi F; Briganti A; Karakiewicz PI; Sun M
    Eur J Surg Oncol; 2014 Jan; 40(1):103-12. PubMed ID: 24099755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score.
    Hansen J; Bianchi M; Sun M; Rink M; Castiglione F; Abdollah F; Steuber T; Ahyai SA; Steurer S; Göbel C; Freschi M; Montorsi F; Shariat SF; Fisch M; Graefen M; Karakiewicz PI; Briganti A; Chun FK
    BJU Int; 2014 Mar; 113(3):399-407. PubMed ID: 24053339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study.
    Abdollah F; Sun M; Thuret R; Abdo A; Morgan M; Jeldres C; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Cancer Causes Control; 2011 Aug; 22(8):1085-95. PubMed ID: 21643929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.
    Preisser F; Mazzone E; Knipper S; Nazzani S; Bandini M; Shariat SF; Tian Z; Saad F; Montorsi F; Zorn KC; Graefen M; Tilki D; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Feb; 17(1):e130-e139. PubMed ID: 30366880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
    Sheng W; Zhang H; Lu Y
    Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.